$FRNM
Freenome, Inc. Common stock
XNAS•Health Care•Services-Medical Laboratories
$14.26
▲+1.42%+$0.200
Subscriptions are live. Early access $24.99/mo, or start with 5 free premium days.
Plans & pricingDonateFreenome, Inc. Common stock
XNAS•Health Care•Services-Medical Laboratories
Why is FRNM up today? It is at $14.26 (+1.42%), and our scanner flagged it 76 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment FRNM spikes, and full due diligence on FRNM — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $FRNM 76 times in the last 30 days. Create a free account to track $FRNM, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Here is the latest on FRNM from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for FRNM today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
Likely catalystFreenome Expands Personalized Cancer Detection Portfolio, Launching SimpleScreen™ Lung Test With FDA-ApprovedReported – In an independent cohort, SimpleScreen Lung showed 85% sensitivity at 50% specificity and a 99.8% negative predictive value for lung cancer in itsReported Lung cancer is the leading cause of cancer death in the United States, and less than 20% of people (more than 10 million individuals) eligible for lung cancer screeningReported lung cancer screening eligibility.5 In an independent cohort of 172 lung cancer cases and 436 controls, the test achieved 85% sensitivity at 50% specificity and a 99.8% negative predictive value (NPV). This NPV means that about two of, from an SEC filing. Read it →Latest filing424B3Final offering prospectus (424B3)Oct 20, 2026 · yesterdayAcross every filing on file, supply equal to 80.5% of the tradeable float is in play - 80.5% has already been sold.
Recent priced share offering — a one-time sale that has already completed (not ongoing)
75,188,742 new shares
Sources: float & market cap via Polygon · short interest via FINRA · borrow & shortability via Alpaca · SSR from Reg SHO 201 · filings & dilution via SEC EDGAR · analysts via Nasdaq.
Auto-generated from public data for research and education. Not investment advice.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Elliott Aaron Matthew Officer | Sold (automatic/other) | -72K 0.07% of company | sold 17% | 346K | $1.1M at $15.25 | Sep 2, 26 |
Ra Capital Management, L.P. Director | Acquired (grant/award) | +14.62M 13.6% of company | added 100% | 15.37M | $146.2M at $10.00 | Jul 20, 26 |
Altman Michael Seth Other | Acquired (grant/award) | +2.07M 1.9% of company | added 100% | 2.35M | n/a | Jul 20, 26 |
Stone Adam Leo Other | Acquired (grant/award) | +2.07M 1.9% of company | added 100% | 2.35M | n/a | Jul 20, 26 |
Mckenna Mark C. Other | Acquired (grant/award) | +30K 0.03% of company | n/a | 30K | n/a | Jul 20, 26 |
Perceptive Advisors Llc Beneficial Owner (10%) | Acquired (grant/award) | +5.50M 5.1% of company | added 100% | 10.87M | $55.0M at $10.00 | Jul 20, 26 |
Perceptive Capital Solutions Holdings Other | Acquired (grant/award) | +2.07M 1.9% of company | added 100% | 2.35M | n/a | Jul 20, 26 |
Song Kenneth Other | Acquired (grant/award) | +30K 0.03% of company | n/a | 30K | n/a | Jul 20, 26 |
Waksal Harlan Other | Acquired (grant/award) | +30K 0.03% of company | n/a | 30K | n/a | Jul 20, 26 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
The tickers our scanner is lighting up most over the last 48 hours.
Comparable names in services-medical laboratories, closest in size first.
Here is the latest on FRNM from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for FRNM today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
FRNM last traded at $14.26, up 1.42% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Freenome, Inc. Common stock (FRNM) is next expected to report earnings on Tuesday, November 10, 2026 (after close), about 20 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
The FRNM Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged FRNM 76 times in the last 30 days.
FRNM (Freenome, Inc. Common stock) trades on XNAS, with a market cap of about $1.51B in the Services-Medical Laboratories sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge FRNM for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$FRNM discussion
Sign in to ask a question or join the discussion.